Frequently asked questions
A 31-amino acid synthetic GLP-1 receptor agonist with 94% sequence homology to human GLP-1. Modified with a C18 fatty diacid chain (albumin binding) and Aib8 substitution (DPP-4 resistance) to extend half-life from ~2 minutes (native GLP-1) to ~168 hours. FDA-approved for type 2 diabetes (2017, 2019) and chronic weight management (2021, cardiovascular risk reduction 2024).[12]
Binds and activates GLP-1 receptors in the pancreas (stimulating glucose-dependent insulin secretion, suppressing glucagon), hypothalamus (reducing appetite via POMC/CART neuronal activation and NPY/AgRP inhibition), and gut (slowing gastric emptying). The combined effect produces sustained caloric deficit and blood glucose lowering documented in Phase 3 trials.[12] [13]
Clinical trials report GI effects as most common: nausea (14–58% across trial arms), diarrhea (~30%), constipation, vomiting — dose-dependent and typically transient. Rare but serious: pancreatitis (HR 1.05 pooled), thyroid C-cell tumor box warning (rodent data, marginal human relevance), retinopathy risk in SUSTAIN-6, aspiration risk under anesthesia due to gastroparesis.[13] [14]
Regulatory literature documents thyroid C-cell tumor risk (from rodent suprapharmacological lifetime exposures; marginal GLP-1R expression in human thyroid makes direct extrapolation uncertain), pancreatitis HR 1.05 in pooled analysis, and aspiration risk during anesthesia from gastroparesis. Post-marketing FAERS signals include intestinal obstruction and cholecystitis — causality not yet established.[14] [18]
Beyond GI tolerability: absolute lean mass decreases alongside fat mass (-9.7% absolute in STEP 1 DEXA substudy[15]); weight regain averaging 11.6 percentage points within one year of discontinuation;[3] and high cost and access barriers documented in health economics literature. The evidence is clear on both the efficacy and the limitations at discontinuation.
STEP 1 DEXA imaging substudy (N=140) documented visceral adipose tissue reduction of 27.4% alongside total fat mass reduction of 19.3%. Absolute lean body mass also decreased 9.7%. The lean-to-fat mass ratio improved overall; visceral fat reduction exceeded total fat reduction proportionally.[15]
A dedicated pharmacokinetic study found no clinically significant AUC effects for metformin, warfarin, atorvastatin, or digoxin — despite gastroparesis-mediated absorption rate changes for atorvastatin (Cmax -38%, AUC unchanged).[11] Insulin secretagogues increase hypoglycemia risk pharmacodynamically. Alcohol use disorder was excluded from Phase 3 trials; GLP-1 receptor agonists may modulate alcohol reward pathways.[17]
STEP 4 withdrawal extension showed approximately 11.6 percentage points weight regain within one year of discontinuation versus peak loss.[3] GI symptoms generally resolve within weeks. No physiological withdrawal syndrome has been identified in trial data. Cardiometabolic biomarker improvements documented during treatment reversed on discontinuation.[8]
STEP trial protocols used a five-step titration: 0.25 mg/week (weeks 1–4), 0.5 mg/week (weeks 5–8), 1.0 mg/week (weeks 9–12), 1.7 mg/week (weeks 13–16), 2.4 mg/week maintenance — designed to minimize GI intolerability. These are FDA-labeled doses from clinical trials, not individual dosing recommendations. PIONEER oral protocol: 3 mg/day escalating to 14 mg/day over 8 weeks.[1] [9]
Body weight reductions statistically detectable at week 4 in STEP 1. Peak efficacy observed between weeks 52–68 at the 2.4 mg maintenance dose. Glycemic effects measurable within 24–48 hours of first dose (postprandial glucose reduction); HbA1c improvements documented at weeks 2–4 in SUSTAIN-1 data. Steady-state plasma concentrations reached after 4–5 weeks of weekly dosing.[1] [10]
Elimination half-life approximately 145–168 hours (approximately one week) for both subcutaneous and oral formulations. Steady-state plasma concentrations reached after 4–5 weeks of continuous once-weekly administration per pharmacokinetic modeling in Phase 1 studies. Metabolized via proteolytic cleavage and beta-oxidation; excreted renally and fecally.[10]
Yes. Semaglutide is a synthetic analogue of human GLP-1 with 94% sequence homology, modified with a C18 fatty diacid chain and two amino acid substitutions (Aib8, Arg34) that extend half-life from approximately 2 minutes (native GLP-1) to approximately 168 hours. The modifications are the basis of the once-weekly subcutaneous or once-daily oral dosing schedules used in clinical trials.[12]
Pooled Phase 3 data across STEP and SUSTAIN programs reports a well-characterized safety profile: most adverse events GI in nature and dose-dependent; serious adverse event rates comparable to placebo except for GI events requiring medical attention in a small percentage of participants.[14] Post-marketing pharmacovigilance has identified additional signals — intestinal obstruction, cholecystitis — where causality has not yet been established.[18]
Semaglutide is a GLP-1 receptor monoagonist; tirzepatide is a dual GIP/GLP-1 receptor agonist. SURMOUNT-5 head-to-head data showed tirzepatide achieving greater mean weight loss than semaglutide 2.4 mg. A 2025 post-hoc analysis found semaglutide produced a mean 1.4% absolute reduction in predicted 10-year CVD risk versus 2.4% for tirzepatide — both significantly exceeded placebo.[R2]
Alopecia reported in 3.3% of semaglutide trial participants versus 1.4% placebo (RR 2.38; 95% CI 1.41–4.0). Participants achieving >20% weight loss had higher rates (5.3% vs 2.5%). Proposed mechanism: telogen effluvium secondary to rapid weight loss-induced physiological stress and potential micronutrient depletion — not listed as a primary adverse event in Phase 3 data.[20]
STEP 1 DEXA substudy (N=140) documented absolute lean body mass decrease of 9.7% with semaglutide at 68 weeks. However, lean mass proportion of total body weight increased 3.0 percentage points — more fat than lean was lost per unit of total weight. Fat mass decreased 19.3%; visceral fat 27.4%.[15] Trials with resistance exercise co-intervention showed attenuated lean mass loss.
Primarily through CNS appetite suppression via GLP-1 receptor activation in the hypothalamic arcuate nucleus (POMC/CART neuronal activation, NPY/AgRP inhibition), delayed gastric emptying reducing meal-time caloric intake, and potential direct effects on adipose metabolism via AMPK/SIRT1 pathway and adipose browning. The combined effect produces a sustained caloric deficit in research subjects.[11] [12]
Semaglutide preparations produced by compounding pharmacies outside the FDA-approved manufacturing chain. FDA has issued multiple warnings regarding compounded GLP-1 products citing dosing errors (including 10-fold overdose cases), product quality concerns, and unapproved ingredient combinations documented in adverse event reports. Compounded versions have not undergone the pharmacokinetic and safety characterization of the approved formulations.
Multiple FDA approvals: subcutaneous injection for type 2 diabetes (2017); oral tablet for type 2 diabetes (2019); subcutaneous injection for chronic weight management in adults with obesity or overweight with weight-related comorbidity (2021); cardiovascular risk reduction label update following SELECT trial results (2024). Compounded semaglutide is not FDA-approved.
GLP-1 receptor activation in the area postrema (a brainstem chemoreceptor trigger zone lacking a blood-brain barrier) and delayed gastric emptying are the proposed mechanisms.[13] Nausea is dose-dependent and most pronounced during escalation phases. STEP 1 data shows prevalence declining from ~44% during escalation to ~20% at maintenance in participants completing the trial.
GI side effects peak during dose escalation (weeks 1–16) and diminish at maintenance dose in most trial participants. Nausea prevalence in STEP 1 declines from approximately 44% at escalation to approximately 20% at maintenance. Persistent GI effects beyond 3–4 months are documented in a minority of participants.[13]
No contraindication established in Phase 3 trials, which excluded alcohol use disorder. Preclinical studies reported reduced alcohol consumption and blunted nucleus accumbens dopamine release via GLP-1 receptor activation in VTA.[17] Observational human data suggests GLP-1RA use linked with ~50% reduced AUD risk in type 2 diabetes patients.[19] This remains an active research area; not a definitive clinical finding.
SUSTAIN-6 and STEP exploratory analyses documented modest reductions in systolic blood pressure — mean approximately 5–6 mmHg — as secondary endpoints. STEP 1 and 4 cardiometabolic analyses: 51.5% versus 38.2% of participants achieved ACC/AHA blood pressure target <130/80 mmHg. Consistent with weight loss-mediated and proposed direct vascular effects.[8]
Pharmacodynamic effects measurable within 24–48 hours of first dose (postprandial glucose reduction). Body weight changes statistically detectable at week 4 in STEP 1. Clinically meaningful weight loss (≥5%) first observed at median week 16–20 in trial populations. Steady-state plasma concentrations reached after 4–5 weeks of weekly dosing.[1] [10]